Home › Activist investors › Shah Capital
Campaign activist. Positions and campaigns from Shah Capital’s SEC filings. Updated November 20, 2026.
No active campaign by this definition (see How to read this).
| Company | Stake | Source | First disclosed | Last change | Since previous filing | Flags | Stated intent |
|---|---|---|---|---|---|---|---|
| Novavax, Inc. | 6.5%10,656,964 shares | Schedule 13D/A, filed Oct 16, 2026 | Apr 15, 2024 | Decreased Oct 16, 2026 | ▼ 2.57 pts | Decreased | Standard Item 4 language |
| Elicio Therapeutics, Inc. | 4.42%1,250,000 shares | 13F, quarter ended Sep 30, 2026filed Oct 9, 2026; % of shares outstanding as of Nov 3, 2026 | Oct 9, 2026 | — | — | New | 13F: none stated |
| Tronox Holdings PLC | 1.83%2,915,807 shares | 13F, quarter ended Sep 30, 2026filed Oct 9, 2026; % of shares outstanding as of Oct 20, 2026 | Nov 12, 2025 | Increased Oct 9, 2026 | ▲ 0.22 pts | Increased | 13F: none stated |
| VEON Ltd. | 6.7%4,620,275 shares | Schedule 13D/A, filed Oct 16, 2026 | Oct 31, 2023 | Increased Oct 21, 2024 | ▼ 0.29 pts | — | Standard Item 4 language |
Stake: the latest 13D’s percent of the class (the largest single reporting person’s, as filed), or for a 13F the reported shares as a percent of the company’s shares outstanding on the date shown. Since previous filing: the change in percentage points against the investor’s previous 13D on the company, or its previous 13F.
Item 4 of a Schedule 13D (“Purpose of Transaction”) is where the investor states its plans. The label is a plain reading of that text; the excerpt is quoted from the filing.
“Effective as of October 16, 2026, Shah Capital filed a Form ADV-W to voluntarily withdraw its registration as an investment adviser with the U.S. Securities and Exchange Commission. Consequently, Shah Capital no longer operates as a registered investment adviser, and the Reporting Persons have updated their regulatory status accordingly. As a result, the Reporting Persons no longer hold the shares”
Item 4 in the Schedule 13D/A filed Oct 16, 2026.
Summary of the filing Shah Capital withdrew its investment-adviser registration and says it no longer holds its Novavax stake with intent to influence control, planning to move to Schedule 13G.
Quoted from the filing (item 4): “Effective as of October 16, 2026, Shah Capital filed a Form ADV-W to voluntarily withdraw its registration as an investment adviser with the U.S. Securities and Exchange Commission.” Oct 16, 2026
“Effective as of October 16, 2026, Shah Capital filed a Form ADV-W to voluntarily withdraw its registration as an investment adviser with the U.S. Securities and Exchange Commission. Consequently, Shah Capital no longer operates as a registered investment adviser, and the Reporting Persons have updated their regulatory status accordingly. As a result, the Reporting Persons no longer hold the shares”
Item 4 in the Schedule 13D/A filed Oct 16, 2026.
Summary of the filing Shah Capital restructured into a family office, deregistered as an investment adviser, and says it will report on Schedule 13G going forward with no present activism plans.
Quoted from the filing (item 4): “the Reporting Persons no longer hold the shares with a purpose of influencing control and intend to report on Schedule 13G going forward” Oct 16, 2026
Campaigns are compiled from SEC filings (13D, proxy contest filings and settlement 8-Ks); campaigns run without SEC filings, e.g. by public letter below the 5% threshold, may not appear.
| Company | Outcome or last status | Date | First filing | Highest stage | Filings | Meeting / votes |
|---|---|---|---|---|---|---|
| Novavax, Inc.Board seatsGovernance changes | Shareholder meeting held after the soliciting material | Jun 17, 2026 | Apr 27, 2023 | Proxy contest filed (preliminary proxy) | latest (12) | — |
| Vitamin Shoppe, Inc.Board seats | Settled (agreement with the company) | Apr 23, 2018 | Apr 23, 2018 | — | latest (3) | — |
| Company | Last stake | Source | Outcome | Date |
|---|---|---|---|---|
| Emeren Group Ltd | 0.0% | Schedule 13D/A, filed Dec 16, 2025 | Exited | Dec 16, 2025 |
Fund votes come from Form N-PX filings, which this site holds from July 1, 2023 (meetings through June 30, 2026; later meetings appear when the managers file their next N-PX); earlier contests and campaigns that settled before a vote are listed under the activist’s campaigns.
No proxy contest has gone to a vote since July 1, 2023.
How each campaign on record ended, as read from the filings: settlements disclosed in the company’s 8-K or the investor’s 13D, contested votes (8-K Item 5.07), withdrawals and 13D amendments below 5%.
| Company | Outcome | Detail | Date | First filing |
|---|---|---|---|---|
| Novavax, Inc. | No outcome in the filings read | — | Jun 17, 2026 | Apr 27, 2023 |
| Vitamin Shoppe, Inc. | Settlement | agreement with the company | May 15, 2018 | Apr 23, 2018 |
The change in the company’s closing share price from the first trading day on or before the investor’s first Schedule 13D to the latest close, and to 6 and 12 months after it, beside the S&P 500 (SPY) over the same dates. This is a price change after a filing date: it is not attributed to the investor, and it is not the investor’s return. Coverage: 0 of 3 13D positions have prices (the site’s daily price history starts November 10, 2025, and covers only listed tickers it tracks).
Terms of the cooperation agreements, read by rules from the company’s Form 8-K (or the investor’s 13D where it describes the agreement). Each term is quoted from the filing; terms a rule did not find are not listed, so a missing term is not evidence that the agreement lacks it.
“(g) Should any Shah Designee resign from the Board or become unable to serve on the Board for any reason before the completion of the 2019 Annual Meeting, Shah Capital will have the right to appoint to the Board a replacement director (a “ Replacement ”) who shall meet the Applicable Criteria and be reasonably acceptable to the Board.” 8-K, Apr 23, 2018
“Upon the appointment of a successor Chief Executive Officer, the Company will increase the size of the Board by one director, and will appoint the successor Chief Executive Officer to the Board. 2 (f) The Company shall hold the 2018 Annual Meeting not later than June 30, 2018.” 8-K, Apr 23, 2018
“…e Common Shares is less than 10% of the then-outstanding Common Shares (the “ 10% Ownership Level ”), (i) Shah Capital shall lose its right to identify one Shah Designee (and his/her Replacement), (ii) the Company shall not be obligated to appoint such Shah Designee, (iii) the Company shall not be obligated to nominate such Shah Designee (or any respective Replacement) for election to the Board at any meeting of stockholders at which directors are to be elected occurring afte…” 8-K, Apr 23, 2018
“…in Shoppe to Appoint New Independent Directors to Board SECAUCUS, N.J. – April 23, 2018 – Vitamin Shoppe, Inc. (NYSE: VSI), an omni-channel, specialty retailer and contract manufacturer of nutritional products, today announced that it will appoint up to five new independent directors to its Board of Directors.” 8-K, Apr 23, 2018
“Pursuant to the cooperation agreements, Shah Capital and Vintage Capital will vote their shares in favor of all of Vitamin Shoppe’s director nominees at the Company’s 2018 and 2019 Annual Meetings of Stockholders and have agreed to abide by customary standstill provisions and voting commitments.” 8-K, Apr 23, 2018
Filings by other activists on this list (their first 13D or 13F on the company) and by other holders of 5% or more (Schedule 13D or 13G) dated within 180 days of Shah Capital’s first disclosure in the same company. They are listed together by date only; nothing here says the holders act together.
| Holder | Form | Date | Stake |
|---|---|---|---|
| FMR LLC | Schedule 13G | Jun 6, 2025 | 0.2% |
| Dimensional Fund Advisors LP | Schedule 13G | Oct 9, 2025 | 5.0% |
| The Vanguard Group | Schedule 13G | Oct 31, 2025 | 6.2% |